Investment Rating - The investment rating for the company is "Buy" [2][4]. Core Insights - The company's performance is under pressure year-on-year due to cost input strategies, but there is a positive trend on a quarter-on-quarter basis. Future revenue growth from new business segments and an improved market landscape is anticipated [4]. - The company has slightly underperformed expectations, leading to a downward revision of profit forecasts. The projected net profits for 2024-2026 are 1.35 billion, 1.89 billion, and 2.48 billion RMB, respectively, with corresponding PE ratios of 51, 37, and 28 times [4]. - Revenue growth is driven by proprietary brands and closed products, with a year-on-year increase of 14.1% and a quarter-on-quarter increase of 16.5% in Q3 2024. The decline in net profit year-on-year is attributed to tax expenses and increased operational costs [4]. - The market for nebulization products is expected to improve, with recent policy signals indicating a more favorable regulatory environment for flavored electronic cigarettes [4]. - The HNB (Heated Not Burned) business is projected to contribute to revenue growth, supported by increased R&D investment and collaboration with BAT to provide comprehensive product and technology solutions [4]. Financial Summary - The company's revenue for 2024 is estimated at 12.42 billion RMB, with a year-on-year growth of 11%. The projected revenues for 2025 and 2026 are 14.29 billion and 16.43 billion RMB, respectively, both reflecting a 15% growth rate [7]. - The net profit for 2024 is forecasted to be 1.35 billion RMB, with a year-on-year decline of 18%. The net profits for 2025 and 2026 are expected to recover to 1.89 billion and 2.48 billion RMB, showing growth rates of 40% and 31% respectively [7]. - The PE ratio for 2024 is projected at 51.4, decreasing to 36.7 in 2025 and 28.0 in 2026, indicating an improving valuation over time [7].

Investment Rating - Buy (Maintained) [1] Core Views - The company's Q3 revenue showed steady growth, driven by its own-brand business and closed-system product revenue from enterprise clients [3] - The company continues to invest heavily in R&D, particularly in heated tobacco (HNB) and medical vaporization products, positioning itself for future growth [4] - The global HNB market is expected to grow at a CAGR of 15.5% from 2023 to 2028, reaching USD 75.51 billion by 2028 [4] - The company is expected to benefit from increasing overseas demand for new tobacco products and potential market share gains from major clients [4] Financial Performance - Q3 2024 revenue reached RMB 3.286 billion, up 14.1% YoY, while net profit declined by 22.5% YoY to RMB 379 million [3] - For the first three quarters of 2024, the company achieved revenue of RMB 8.323 billion, up 4.0% YoY, and net profit of RMB 1.062 billion, down 11.9% YoY [3] - The company's own-brand revenue grew by 71.9% YoY in the first half of 2024, reaching RMB 1.116 billion, with continued strong growth expected in Q3 [3] - R&D expenses increased by 23.7% YoY in the first half of 2024, reaching RMB 760 million [4] Future Projections - The company is expected to achieve net profits of RMB 1.7 billion, RMB 2.05 billion, and RMB 2.48 billion for 2024, 2025, and 2026, respectively [4] - Revenue is projected to grow at a CAGR of 19.87% and 16.65% in 2025 and 2026, respectively [5] - Net profit growth is expected to accelerate to 20.45% and 20.98% in 2025 and 2026, respectively [5] - The company's PE ratio is forecasted to be 43x, 35x, and 29x for 2024, 2025, and 2026, respectively [4] Business Strategy - The company is focusing on digital marketing and rapid response to consumer demand for its own-brand products [3] - It is expanding its international market presence and localizing operations to enhance its competitive edge [3] - The company's HNB product portfolio is gaining recognition, and potential orders from major clients like British American Tobacco could drive future growth [4] Financial Ratios - The company's gross margin is expected to improve from 38.81% in 2023 to 40.88% by 2026 [7] - ROE is projected to increase from 7.68% in 2023 to 9.05% by 2026 [7] - The company's net debt ratio is expected to remain negative, indicating a strong financial position [7]

Investment Rating - Buy rating maintained for Smoore International (6969 HK) [1] Core Views - Smoore International's 2024H1 results were largely in line with expectations, with revenue of RMB 5 037 million (-1 7% YoY) and net profit of RMB 683 million (-4 8% YoY) [1] - The company's self-branded business showed strong growth, with revenue increasing by 71 9% YoY to RMB 1 116 million, driven by new product launches and market share gains [1] - Smoore's gross margin improved by 1 8 percentage points to 38 0% in 2024H1, mainly due to the expansion of higher-margin self-branded business and cost optimization efforts [1] - The company is expected to benefit from industry consolidation amid tightening global regulations, leveraging its compliance capabilities, technological advantages, and flexible business model [1] Business Performance - Self-branded business revenue grew significantly in Europe (88% YoY) and the US (20 6% YoY) in 2024H1 [1] - Enterprise client business revenue declined by 12 3% YoY, with mixed performance across regions: US (-9 8%), Mainland China (+41 4%), Europe (-16 0%) [1] - Smoore increased its R&D investment, particularly in medical vaporization and heat-not-burn products, with R&D expense ratio rising by 3 08 percentage points to 15 09% [1] Financial Projections - Revenue is forecasted to grow 6% in 2024, 15% in 2025, and 11% in 2026, reaching RMB 11 811 million, RMB 13 583 million, and RMB 15 033 million respectively [1][2] - Net profit is expected to be RMB 1 632 million (-1% YoY) in 2024, RMB 1 915 million (+17% YoY) in 2025, and RMB 2 134 million (+11% YoY) in 2026 [1][2] - EPS projections are RMB 0 27 (2024), RMB 0 31 (2025), and RMB 0 35 (2026), with corresponding P/E ratios of 31 38x, 26 75x, and 23 99x [1][2] Financial Ratios - ROE is expected to remain stable at around 7 08%-7 88% from 2024 to 2026 [2] - Gross margin is projected to maintain at approximately 38 0%-38 4% over the next three years [5] - The company's net debt ratio is expected to stay negative, indicating a strong financial position [5]

Financial Performance - The group's revenue for the six months ended June 30, 2024, was RMB 5,037,242 thousand, a decrease of 1.7% compared to RMB 5,122,862 thousand in the same period of 2023 [20]. - Gross profit increased by 3.2% to RMB 1,914,597 thousand, with a gross margin of 38.0%, up 1.8 percentage points from 36.2% in 2023 [20]. - The net profit margin decreased to 13.6% from 14.0% in the previous year, with net profit for the period at RMB 683,198 thousand, down 4.8% from RMB 717,342 thousand [20]. - The comprehensive income for the period was approximately RMB 724.60 million, a decrease of about 1.3% compared to the same period last year [70]. - Basic earnings per share decreased to RMB 11.20 from RMB 11.81, reflecting a decline of 5.2% year-over-year [197]. - The total revenue for the group during the review period was approximately RMB 5,037.24 million, a decrease of about 1.7% compared to the same period last year [70]. Research and Development - The company continued to increase R&D investment in the first half of 2024, focusing on aerosol medical and heated non-combustible products, with expectations for new revenue and profit growth points [13]. - Research and development expenditure totaled approximately RMB 760,112 thousand, an increase of about 23.7% compared to the previous year, with R&D spending as a percentage of revenue rising from approximately 12.0% to about 15.1% [57]. - The R&D team consists of over 1,400 personnel, with significant investment in innovation to support long-term growth and maintain competitive advantages [49]. - The company filed a total of 699 new patent applications globally during the review period, including 401 invention patents, bringing the total to 8,394 patents as of June 30, 2024 [54]. Product Development and Launches - The company launched multiple new products, including the FEELM Pro and the XROS 4, which received positive feedback and contributed to rapid revenue growth in its proprietary brand business [10]. - The atomization beauty product "MOYAL" was successfully launched, being the first in the industry to atomize high-viscosity serums, and is currently in the channel development phase [12]. - The company successfully launched several new product solutions in the first half of 2024, including the world's first 20,000 puff high-explosion dual-core disposable solution [25]. - The company plans to launch more innovative products in the second half of 2024 to enhance its product matrix and market share [15]. Market Expansion and Strategy - The company is actively advancing its atomization technology into new business areas, with steady progress in atomization medical and beauty sectors [12]. - The company is focusing on localizing its sales teams and enhancing delivery capabilities to better meet consumer preferences [12]. - The company plans to diversify its revenue across different countries and regions and enhance its product portfolio, focusing on the application of aerosol technology in healthcare and other industries [39]. - The company is committed to building a global leading aerosol technology platform, with confidence in the long-term growth of the global aerosol market [60]. Financial Position and Assets - The total assets of the group as of June 30, 2024, reached RMB 26,540,994 thousand, representing a 4.0% increase from RMB 25,508,284 thousand at the end of 2023 [20]. - Cash and cash equivalents increased by 22.6% to RMB 6,534,871 thousand from RMB 5,332,076 thousand at the end of 2023 [20]. - As of June 30, 2024, net current assets were approximately RMB 13,861,870 thousand, down from RMB 16,004,419 thousand as of December 31, 2023 [102]. - The current ratio as of June 30, 2024, was approximately 396.2%, down from 548.8% as of December 31, 2023 [102]. Regulatory Environment - The regulatory environment for electronic atomization products is strengthening, which is expected to benefit the long-term development of the industry [10]. - The EU's new regulations require all tobacco products to have unique identification codes, enhancing traceability and compliance [34]. - Belgium has received EU approval to implement a ban on disposable e-cigarettes, set to take effect on January 1, 2025 [35]. Shareholder and Governance - The board declared an interim dividend of HKD 0.05 per share for the six months ended June 30, 2024, consistent with the previous year [145]. - The company has established an ESG committee to enhance its ESG management capabilities [131]. - The company has established various communication channels with shareholders and investors to provide updates and gather feedback [141]. - The board of directors believes that the current governance structure is appropriate for shareholder interests and will continue to review its effectiveness [123]. Employee and Operational Efficiency - The company emphasizes employee training and development, with structured programs for various talent levels and a focus on online learning [110]. - The company is focusing on cost reduction and efficiency improvements, successfully achieving a significant decrease in administrative expenses during the review period [27]. - Employee compensation and benefits increased by 37.1% to RMB 148,642 thousand, accounting for 3.0% of total revenue [88]. Future Outlook - The company has outlined a future outlook with a focus on market expansion and new product development [1]. - The company projects a revenue growth of 2.99% to 3.51% for the periods ending in 2025 and 2026, respectively [1]. - The company plans to continue its strategy of incentivizing key personnel through the share incentive plan to drive further growth [169].

上 市 公 司 电子 公 司 点 评 / 公 司 点 评 报告原因：有业绩公布需要点评 | --- | --- | |------------------------|---------------------| | 市场数据： | 2024 年 08 月 23 日 | | 收盘价（港币） | 8.94 | | 恒生中国企业指数 | 6219.24 | | 52 周最高/最低（港币） | 10.52/4.61 | | H 股市值（亿港币） | 548.76 | | 流通 H 股（百万股） | 6,138.24 | | 汇率（人民币/港币） | 1.0926 | 一年内股价与基准指数对比走势： -34% 16% 66% HSCEI 思摩尔国际 资料来源：Bloomberg 证券分析师 屠亦婷 A0230512080003 tuyt@swsresearch.com 研究支持 张文静 A0230122100001 zhangwj@swsresearch.com 联系人 张文静 (8621)23297818× zhangwj@swsresearch.com 2024 年 08 月 26 日 思摩尔国际 (06969) ...

Investment Rating - The report maintains a Buy-A rating for Smoore International (06969 HK) with a 6-month target price of HKD 12 12 [4] Core Views - Smoore International's self-owned brand business showed strong growth in H1 2024 with revenue increasing by 71 94% YoY to RMB 1 116 billion while ODM revenue declined by 12 35% YoY to RMB 3 922 billion [2] - The company's gross margin improved to 38 0% in H1 2024 up 1 8 percentage points YoY driven by the higher proportion of high-margin self-owned brand business and cost reduction efforts [3] - Smoore International is expected to achieve revenue of RMB 12 357 billion in 2024 representing a YoY growth of 10 65% with adjusted net profit of RMB 1 694 billion a YoY increase of 0 95% [3] Business Performance - In H1 2024 Smoore's self-owned brand VAPORESSO continued to gain market share in the open-system product category with revenue from Europe and other markets surging 88 0% YoY to RMB 929 million and US revenue growing 20 6% YoY to RMB 187 million [2] - The company's enterprise-facing sales showed signs of recovery with US revenue declining 9 8% YoY to RMB 1 858 billion and European revenue down 16 0% YoY to RMB 1 976 billion However Q2 2024 saw a sequential recovery with US revenue up 6 1% QoQ and European closed-system pod revenue surging 93 2% QoQ [2] Financial Performance - Smoore's H1 2024 revenue decreased by 1 67% YoY to RMB 5 037 billion while net profit attributable to shareholders declined by 4 76% YoY to RMB 683 million [1] - The company's adjusted net profit margin in H1 2024 was 13 6% down 0 4 percentage points YoY due to increased sales and R&D expenses [3] Valuation and Forecast - The report forecasts Smoore's revenue to grow to RMB 14 024 billion in 2025 and RMB 15 702 billion in 2026 with adjusted net profit expected to reach RMB 1 891 billion and RMB 2 164 billion respectively [3] - Smoore's PE ratio is projected to be 31 6x 30 8x and 27 6x for 2024 2025 and 2026 respectively [3]

Investment Rating - Buy rating maintained for Smoore International (6969 HK) [4] Core Views - Smoore International reported H1 2024 revenue/net profit/total comprehensive income of RMB 5 037/683/725 million down 2%/5%/1% YoY [2][5] - Self-branded business grew strongly with Q2 pod product sales recovering and showing growth momentum [6] - R&D investments in HNB and atomization products driving long-term growth [7] Revenue Analysis - TOB business revenue declined 12% YoY in H1 2024 accounting for 78% of total revenue [6] - US/China/Europe & other regions revenue changed -10%/+41%/-16% YoY respectively [6] - Disposable/pod & HNB/APV product revenue was RMB 1 217/2 704/1 116 million changing -19%/-9%/+72% YoY [6] - US pod product revenue grew 6 1% QoQ and 6 5% YoY in Q2 [6] - Europe & other regions pod product revenue surged 93 2% QoQ and 22 5% YoY in Q2 [6] - TOC business revenue jumped 72% YoY in H1 2024 with share rising 9pcts to 22% [6] - US/Europe & other regions revenue increased 20 6%/88 0% YoY [6] - New XROS 4 product became a market hit [6] - VAPORESSO brand strengthened its leading position in open system products [6] Profitability Analysis - Gross margin improved 1 8pcts to 38 0% in H1 2024 driven by [6] - Higher-margin self-branded products gaining share [6] - Lower-margin disposable products declining [6] - Net profit declined 5% YoY in H1 2024 due to [6] - Sales expense ratio up 3 3pcts to 7 4% from international market expansion and new product launches [6] - R&D expense ratio up 3 1pcts to 15 1% from increased investments in medical atomization and HNB [6] - Management expense ratio down 2 4pcts to 6 7% from cost control and efficiency improvements [6] R&D and Growth Prospects - HNB R&D spending increased 15% YoY in H1 2024 with differentiated product solutions developed [7] - Atomization product R&D spending accounted for 24 4% of total in H1 2024 up from 18 5% in H1 2023 [7] - Launched MOYAL skincare brand and first-generation atomization beauty product solution in Q1 2024 [7] - Completed development of several drug delivery devices for asthma and COPD and 10+ drug formulations in H1 2024 [7] - Leading compliant brands expected to gain market share amid tightening regulations [7] - Key client VUSE held 51 2% US market share (closed system and disposable products) as of H1 2024 [7] - Forecast 2024-2026 net profit of RMB 1 660/1 910/2 160 million with PE of 29/25/22X [7]

Investment Rating - The report maintains a "Buy" rating for Smoore International Holdings (6969.HK) with a target price of HKD 10.7, indicating a potential upside of 17% from the current price of HKD 9.12 [3][4]. Core Insights - Smoore's revenue for the first half of 2024 was HKD 50.3 billion, a year-on-year decrease of 1.7%, while net profit was HKD 6.8 billion, down 4.8% year-on-year. The gross margin improved to 38%, up 1.8 percentage points, while the net margin slightly decreased to 13.6%, down 0.4 percentage points [1]. - The company's proprietary brand products saw significant growth, with APV product revenue reaching HKD 11.1 billion, a 72% increase year-on-year. The European market experienced an 88% revenue growth, while the U.S. market grew by 20% [1]. - The report anticipates a recovery in the domestic market, with a 41% year-on-year increase in revenue from 2B products in China, suggesting that the compliant market has likely bottomed out [1]. Financial Performance Summary - Revenue and Profit Forecasts: The expected net profits for 2024, 2025, and 2026 are HKD 16.5 billion, HKD 19.0 billion, and HKD 21.0 billion, respectively, with corresponding EPS of HKD 0.29, HKD 0.34, and HKD 0.38 [1][7]. - Sales and Cost Structure: The sales expenses increased significantly by 70% to HKD 7.6 billion, primarily due to increased marketing investments in proprietary brands and beauty products. Management expenses decreased by 27% to HKD 3.4 billion [1][15]. - R&D Investment: R&D expenses for the first half of 2024 were HKD 7.6 billion, accounting for 15.1% of revenue, reflecting a year-on-year increase of 3.1 percentage points. The company is focusing on medical and beauty product development, with a 63% increase in related R&D spending [1][15]. Market Dynamics - The report highlights a shift in European regulations favoring refillable products, which is expected to boost demand for Smoore's products in the region. The company's 2B business in Europe and other markets saw a revenue decline of 16% due to stricter regulations on disposable products, but the demand for refillable products is anticipated to recover [1]. - In the U.S. market, Smoore has the highest number of PMTA certifications among its clients, which is expected to enhance its market position as regulatory enforcement strengthens [1]. Valuation Analysis - The report employs DCF and PE valuation models, estimating a fair valuation of HKD 66.1 billion, corresponding to a target price of HKD 11.1. The average PE for the electronic cigarette industry is projected at 11.3x for 2025, and considering Smoore's market leadership, a PE of 30x is applied for 2025, leading to a target price of HKD 10.2. The final target price of HKD 10.7 reflects a blend of these valuation methods [7][10].

Investment Rating - The report suggests maintaining attention on the company due to its strategic clarity and solid fundamentals [2]. Core Insights - The company reported a revenue of 5.037 billion RMB for the first half of 2024, a year-on-year decrease of 1.7%. However, gross profit increased by 3.2% to 1.915 billion RMB, while net profit fell by 4.8% to 683 million RMB [1]. - The self-owned brand (APV) business saw significant growth, contributing 1.12 billion RMB in revenue, a year-on-year increase of 71.9%. The European and other markets experienced a rapid rise of 88%, while the US market grew by 20.6% [1]. - The company is focusing on cost management, with distribution and sales, administrative, and R&D expense ratios at 7.4%, 6.7%, and 15.1% respectively, showing changes of +3.3pp, -2.4pp, and +3.1pp year-on-year [1]. - The ODM segment aimed at enterprise clients is in a recovery phase, with reported revenue of 3.92 billion RMB. The European market saw a decline of 16%, while the US market decreased by 9.8%. In contrast, the Chinese market experienced a growth of 41.4% [1]. - The company continues to innovate, launching the MOYAL brand and developing products for asthma and COPD drug delivery systems [2].

Investment Rating - The report suggests maintaining attention on the company due to its solid fundamentals and clear strategic planning [2]. Core Insights - The company's revenue for the first half of 2024 was 5.037 billion RMB, a year-on-year decrease of 1.7%, while gross profit increased by 3.2% to 1.915 billion RMB, and net profit decreased by 4.8% to 683 million RMB [1]. - The self-owned brand (APV) business saw significant growth, contributing 1.12 billion RMB in revenue, a year-on-year increase of 71.9%, with notable growth in Europe and other markets at 88% and the US market at 20.6% [1]. - The company is focusing on cost management, with distribution and sales, administrative, and R&D expense ratios at 7.4%, 6.7%, and 15.1% respectively, showing changes of +3.3pp, -2.4pp, and +3.1pp year-on-year [1]. - The ODM segment aimed at enterprise clients reported revenue of 3.92 billion RMB, with a decline in Europe by 16% and in the US by 9.8%, while China saw an increase of 41.4% [1]. - The company is actively innovating, launching the MOYAL brand in the beauty aerosol field and developing devices for asthma and COPD medication delivery [2]. Summary by Sections Revenue Performance - Total revenue for the first half of 2024 was 5.037 billion RMB, down 1.7% year-on-year [1]. - Gross profit reached 1.915 billion RMB, up 3.2% year-on-year [1]. - Net profit was 683 million RMB, a decrease of 4.8% year-on-year [1]. Self-Owned Brand Growth - Revenue from self-owned brands (APV) was 1.12 billion RMB, increasing by 71.9% year-on-year [1]. - Growth in Europe and other markets was 88%, while the US market grew by 20.6% [1]. Cost Management - Distribution and sales expenses increased, with ratios at 7.4%, while administrative expenses were at 6.7% and R&D expenses at 15.1% [1]. - Year-on-year changes in expense ratios were +3.3pp for distribution and sales, -2.4pp for administrative, and +3.1pp for R&D [1]. ODM Segment Performance - Revenue from the ODM segment was 3.92 billion RMB, with a 16% decline in Europe and a 9.8% decline in the US, while China saw a 41.4% increase [1]. Innovation and Product Development - The company launched the MOYAL brand in the beauty aerosol sector and developed devices for asthma and COPD medication delivery [2].